Read as much as you want on BostonGlobe.com, anywhere and anytime, for just 99¢.

MAP Pharmaceuticals Inc.

Continue reading below

The Food and Drug Administration will review MAP Pharmaceuticals Inc.’s experimental migraine drug Levadex, the Mountain View, Calif., company said. Levadex is an orally inhaled drug proposed to treat migraines in adults. The biopharmaceutical company focuses on developing new therapies to address patient needs in neurology.

Loading comments...
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com